A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

Study Summary

KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).

Conditions

Dystrophic Epidermolysis Bullosa DEB - Dystrophic Epidermolysis Bullosa Recessive Dystrophic Epidermolysis Bullosa Dominant Dystrophic Epidermolysis Bullosa

Interventions / Drugs

KB803 Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment16 participants

Primary Completion—

Lead SponsorKrystal Biotech, Inc.

Data Retrieved2026-04-11 04:19:09.549443+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.